Island Pharmaceuticals Ltd. is repurposing a known medicine to address the global health crisis of mosquito-borne diseases like dengue fever.
Photo from Google
Island Pharmaceuticals Repurposes Drug for Global Mosquito-Borne Disease Threat
Dengue illness affects 390 million people annually, causing concern. The fact that 30-50% of infected people have no symptoms makes the virus spread quietly throughout communities. Due to a rising global environment, mosquito-borne viruses may spread to the US, Europe, and Australia.
The only dengue fever vaccine is offered to a limited population, and there are no medicinal therapies. This needs effective treatments. Island Pharmaceuticals Ltd., an infectious disease drug development and repurposing business, is leading this effort.
ISLA-101, Island Pharmaceuticals’ key asset, is being repurposed in a novel way. The company’s affiliate Isla Pharmaceuticals created ISLA-101, which has a strong clinical and safety record. The medicine is being re-engineered as an anti-viral to prevent and cure dengue and other mosquito- and vector-borne infections.
ISLA-101: Island Pharmaceuticals’ Innovative Approach to Combatting Mosquito-Borne Viruses
ISLA-101’s unique method targets viral-host protein interaction, a common mosquito-borne virus route. Beyond dengue fever, Island Pharmaceuticals wants to explore ISLA-101 in Phase 2 clinical trials as a broad-spectrum prevention or treatment for Zika, Yellow River Fever, Japanese Encephalitis, and West Nile virus.
Island Pharmaceuticals’ repurposing business strategy accelerates ISLA-101’s clinical application by using existing data and safety profiles. This method cuts development time and costs and navigates the regulatory landscape utilizing existing data. Island Pharmaceuticals is helping fight mosquito-borne infections worldwide by repurposing ISLA-101. The company’s cost-effective and creative pipeline could change world health.
